Over the past three months I, probably like most have benefitted from the movement in small micro - cap stock that have risen heavily on increased liquidity. The next stock, despite having benefitted from a massive surge in share price back in April, that I have focused on is Ultrasis. This company is poised to secure the ever increasing Mental Health Market both at home and in the US (Several lucrative contracts already announced)through its suite of highly effective software.

The companies web address is as follows http://www.ultrasis.co.uk

I for one have gone heavily into this stock and am prepared to wait for the realisation of its potential to kick in .I would advise others to do so

DYOR

Foam treatment for varicose veins

More than a fifth of adults get varicose veins
Injecting patients with a foam that expands in the blood vessels can successfully treat troublesome varicose veins, say doctors.
Between 20% and 30% of adults develop varicose veins, usually later in life or during pregnancy.

As well as looking unpleasant, varicose veins can ache, throb and itch.

More than 50 patients at Ealing Hospital in London have received the foam therapy with good results, says consultant Mr George Geroulakos.

Fast foam

If they are small, varicose veins may be controlled with conservative methods, such as compression bandages or stockings.

But larger or more complicated varices cases will need surgery.

The early and interim results are really promising

Mr George Geroulakos

This can involve stripping the veins, tying them off or injecting an agent to close the vein, which is called sclerotherapy.

Sclerotherapy has some advantages over surgical stripping.

It can be done under local rather than general anaesthetic and leaves only one small scar in the groin rather than numerous scars on the leg.

"With the conventional stripping technique, the patient has to stay off work for about eight days after.

"With the foam therapy, they can go back within days," said Mr Geroulakos, who is also a consultant for the Hammersmith Hospitals NHS Trust.

Doctors have been using liquid sclerotherapy for years. But a newer way is to use a foam, guided with the help of ultrasound imaging.

Closing the vein

In contrast to liquid, foam is not diluted once injected, so less is needed and it remains in the vein for a longer time.

The foam works by pushing the blood out of the way and is able to make better contact with the inside of the vein walls.

All of these factors mean it could work better than liquid sclerotherapy, according to Mr Geroulakos.

"Sometimes the liquid can leak outside of the vein and this can cause a chemical sore or ulcer.

"We think complications should be less common with the foam.

"Plus you can see exactly where the foam is with ultrasound. It casts a shadow that can be seen with the machine. You can see every individual vein, which is a major advantage," he said.

Mr Geroulakos has been treating patients with the foam technique for two years. "The early and interim results are really promising, but we have not been doing it long enough to know about the long-term results," he said.

About a fifth of patients who have their varicose veins treated with stripping will need repeat treatment within five years because the problem comes back. But it is not yet clear whether the same is true with foam therapy.

A single injection of the foam is enough to treat a half metre length of vein.

Afterwards, the patient wears a compression stocking continuously for two weeks and then during the day only for another week.



From the BBC site http://news.bbc.co.uk/2/hi/health/4510709.stm

LONDON (AFX) - Interactive healthcare specialists, Ultrasis PLC said it has secured an order for a new generation of online healthcare programmes from Ashton, Leigh and Wigan Primary Care Trust.

The initiative provides round the clock access to Ultrasis' Relief Series throughout the region. It is a selection of online multimedia programs which provide tools to identify, educate, motivate and monitor people suffering from anxiety, depression, stress and insomnia.

newsdesk@afxnews.com

ra

Topped up.

Good steady buying volume today.

Have been with this since early March - topped up as well in between . Normally with the news likes of yesterday it would shoot up like first week in April it was 1.29 - looks like at the moment markets are jittery and not many want to plunge.
p/271

Lots of sales today - any one has any news ???

Although all shown as sells, 0.65p and above are buys.

I am still in on theses although down at the moment, no problem they tend to take of when a juicy announcement is issued.

Have been in and out of these shares (by luck at the right times) but reckon once the pep/isa sellers are out of the way by 23/5 and the aim listing is a fait a compli that this share will be worth buying again as NICE announcement in July should be good news

robinhood
I agree, but the pep /isa sellers, do not have to sell just open a new account.

i know, but reckon that quite a few won't bother as the sp has not been performing very well and will just liquidate position.

I don't see a sound plan behind an online health product, but nevertheless, it does sound really cheap. Considering the fundamental behind the company, it is almost implying that it has no right to exist in the first place with very bad track records for any earnings at all for the past few years. I am very skeptical of putting my money in this (I got burnt on this a few years back when it jumped to 0.77p, at the peak I bought it, and nose dived down to 0.30p weeks later). I bet same happened this time, 1.2p then nose dived back down again. Perhaps, I should wait till it bottom up at roughly 0.33 - 0.40p then I would dive in again? Need a very very long strategy on this one.

slkhlaw
I understand your concerns, they are going to the Aim Market, and going to raise money, to be put to good use we hope, but with the new appointment of DIRECTOR OF SALES I am hoping that new orders will be flowing, I think punters should take a position and add on a price drop.


New Appointment Announcement

ULTRASIS APPOINTS NEW UK DIRECTOR OF SALES
Interactive healthcare specialists, Ultrasis plc, have appointed a new UK
Director of Sales in order to harvest increasing market potential. Assuming his
new position as of 1st of May, John Smith will develop the market for the
company's range of computer based products, both amongst Primary Care Trusts
keen to use effective drug-free alternatives in the treatment of depression, as
well as employers who in line with current legislation wish to take proactive
steps to reduce stress in the workplace.

slkhlaw
This is also very significant news 25/3/2005

NICE RECOMMENDATION FOR 'BEATING THE BLUES'

Beating the Blues, the flagship product of leading UK based interactive
healthcare company, Ultrasis plc, has been recommended for use as a proven, cost
effective option for treatment of mild and moderate depression in an Appraisal
Consultation Document produced by the National Institute for Clinical Excellence
(NICE).

Ultrasis PLC
23 May 2005


Ultrasis PLC

PILOT COULD PAVE THE WAY FOR BEATING THE BLUES IN THE US

A trial providing a non-drug alternative treatment for patients with depression
in the United States could yield significant opportunities for Ultrasis plc. The
pilot project, which goes live in New York State next month, is particularly
significant as professionals providing the treatment will be piloting its
reimbursement through the US healthcare billing system.

In this model, patients at the SUNY Upstate Medical University at Syracuse in
New York State will be able to benefit from an effective treatment for anxiety
and depression called Beating the Blues, which is a Computerised Cognitive
Behaviour Therapy (CCBT) developed by London based interactive healthcare
specialist, Ultrasis.

CCBT is a generic term that is used to refer to a number of methods of
delivering Cognitive Behaviour Therapy (CBT) via an interactive computer
interface as an alternative to traditional face to face therapy.

Designed for people with no previous computer experience, Beating the Blues
offers a complete self-help therapy, presented in eight weekly modules of one
hour sessions taking place at a local mental health centre. The program uses
interactive modules, animation and voice-overs to engage and motivate the user.

Clinically shown to be effective in Randomised Controlled Trials, Beating the
Blues has recently been recommended in the UK as an effective treatment for mild
and moderate depression in an Appraisal Consultation Document by the National
Institute for Clinical Excellence (NICE).

As John Hill, Vice President of Ultrasis Inc, the wholly owned US subsidiary of
the UK interactive healthcare plc explains, the trial in the US is particularly
significant as providers, for the first time, will investigate having the
associated costs covered by insurance carriers.
'To date, the major stumbling block in prescribing Beating the Blues in the US
has not been the effectiveness of the treatment itself, but rather its lack of a
unique billing code, which is a cornerstone of the US healthcare system.'

He added, 'In the SUNY Upstate Medical University project, each patient will be
seen during each session by a member of the team led by Dr Thomas Schwartz MD,
Assistant Professor of Psychiatry before and after each module in the Beating
the Blues programme. This will meet the requirement of face to face
consultations stipulated by insurance.'

Commenting at the beginning of this pilot programme, Ultrasis plc CEO Graham
Lewis said, 'This is a important step for Ultrasis in the US market, where
latest figures estimate that millions of people are suffering from anxiety,
stress and depression. With a clinically effective product, a growing acceptance
of the need to look at new, non-pharmaceutical ways of treating what is a major
social and economic problem, the remaining hurdle is one of funding.'

'If the project is successful, patients will be able to benefit from the
treatment safe in the knowledge that the associated costs will be funded just
like any other medical treatment. The roll out opportunities, in NY State and
beyond, could be significant and pave the way for growth in one of the world's
largest healthcare markets.'

In a related development, Ultrasis Inc has also announced today a partnership
with the Center for Evidenced-Based Community Psychiatry of The SUNY Upstate
Medical University. The partnership will allow for collaboration between an
academic medical center and a corporation to provide e-therapy solutions
nationally.

John Hill stated, 'This partnership will provide a respected research
institution access to proven e-therapy tools, while providing Ultrasis access to
grant funded research initially focusing on rural access to services.' In
addition to pursuing research, the partnership will explore other development
opportunities and sales opportunities in the government, academic and publicly
funded sectors.

ENDS

This is good bit of News:

Commenting at the beginning of this pilot programme, Ultrasis plc CEO Graham
Lewis said, 'This is a important step for Ultrasis in the US market,

news.news.news the market is growing tired of news,i think a 20/30%rise will trigger a huge wave of sells.this share is now a yoyo (buy today sell tomorrow
for a quick 20%,i will buy back at 0.45,and if i am wrong then goodby

Over 50M shares traded so far today - over 5% of issued capital. If history is anything to go by, this will continue to rise for the remainder of the week.

plm2349

I do under stand your point and that is what seems to happen, but I think long term the sp will brake out again through the 2p and onwards.

the interesting thing to me is the narrowing of the spread, making it much more attractive for short term trading. this might help keep it liquid for a while, and on the back of a good news article may make it a winner over the next couple of weeks.
alan